Dova Pharmaceuticals Inc logo

DOVA - Dova Pharmaceuticals Inc News Story

$28.04 0.0  0.0%

Last Trade - 11/11/19

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £9.72m
Position in Universe th / 6846

BUZZ-Dova Pharmaceuticals Inc: Rises after Raymond James starts with "outperform"

Wed 29th August, 2018 1:11pm
** Drug developer's  DOVA.O  shares up 6 pct at $26.05 in
light premarket trading 
    ** Brokerage Raymond James starts coverage on stock with
"outperform" rating; PT $44
    ** Brokerage says recently approved Doptelet, novel
treatment for low platelet count, begins its U.S. commercial
launch, thinks setup for DOVA appears "attractive"
    ** Says thrombocytopenia market is to the tune of over 7 mln
patients with chronic liver disease, a common complication among
people suffering from thrombocytopenia, a condition in which
blood platelet count becomes low
    ** Doptelet to bring in $11 mln revenue in its first year of
launch, with worldwide end-user revenue reaching $1.04 bln by
2026, brokerage says
    ** Including Raymond James, 4 of 6 brokerages covering the
stock rate it "buy" or higher, 2 "hold"; Median PT $40
    ** Up to Tuesday's close, stock down ~15 pct this year

 (Reporting by Aakash Jagadeesh Babu in Bengaluru)
 ((Aakash.B@thomsonreuters.com; within the U.S. +16462238780,
outside the U.S. +91  80 67491576; Reuters Messaging:
Aakash.B.thomsonreuters.com@reuters.net))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.